Evaxion Biotech Announces Changes to ADS Ratio
Evaxion Biotech A/S (NASDAQ: EVAX), a leader in the TechBio sector focusing on AI-powered vaccines, has made an important announcement regarding the adjustment of the ratio of its American Depositary Shares (ADS) to its ordinary shares. This decision reflects Evaxion's commitment to enhancing investor liquidity as it continues to innovate in immunotherapy solutions.
Impact of the ADS Ratio Change
The company is set to alter the ADS ratio from one (1) ADS representing ten (10) ordinary shares to a new ratio of one (1) ADS representing fifty (50) ordinary shares. This shift is not merely a technical adjustment; rather, it functions like a one-for-five reverse ADS split, which Evaxion anticipates will support the trading activity in the company's ADSs.
Understanding the Exchange Process
For those holding certificated ADSs, mandatory action will be required on the effective date for the new ratio, scheduled around January 14, 2025. Shareholders will need to surrender their current ADS certificates to The Bank of New York Mellon, which serves as the depositary bank. In exchange, they will receive one new ADS for every five existing ADSs held. Thankfully, holders of uncertificated ADSs in the Direct Registration System (DRS) will automatically have their shares converted without needing to take additional steps.
Maintaining Market Sentiment
The adjustment in the ADS ratio is expected to have a proportional effect on the ADS trading price, though the company acknowledges that predicting market responses can be complex. There’s an inherent uncertainty as to whether the trading price will attain or surpass pre-modification levels. However, Evaxion remains optimistic about the liquidity this will foster in the market.
Business Outlook and Innovation
Evaxion is not just focused on shares and ratios; its core mission revolves around innovating immunotherapies through advanced AI technology. The company’s AI-Immunology™ platform stands at the forefront of its strategy, driving the development of personalized vaccines targeting cancer, bacterial diseases, and viral infections. This dedication to utilizing cutting-edge technology underscores Evaxion's goal to transform healthcare outcomes for patients.
Future Prospects
As Evaxion continues to expand its portfolio and enhance its operations, it prioritizes not only the financial aspects of its business but also the life-changing potential of its therapeutic offerings. The forward-thinking approach integrated into the company's operations reflects its readiness to adapt to evolving market dynamics and patient needs.
Contact Information
For more details regarding the company and any inquiries, interested parties can reach out to:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
Email: mak@evaxion.ai
Frequently Asked Questions
What is the new ADS ratio for Evaxion?
The new ADS ratio will change from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares.
When will the new ADS ratio take effect?
The effective date for the ADS ratio change is scheduled for January 14, 2025.
What must ADS holders do on the effective date?
Holders of certificated ADSs must surrender their certificates to The Bank of New York Mellon to receive new ADSs based on the new ratio.
Will holders of uncertificated ADSs need to take any action?
No action is needed from holders of uncertificated ADSs as the exchange will occur automatically.
How does the ADS ratio change affect trading?
The change is designed to enhance liquidity, and while a proportional increase in the trading price is expected, actual outcomes may vary.
